Keyphrases
Focal Segmental Glomerulosclerosis
100%
Pirfenidone
100%
Renal Function Decline
100%
Baseline Period
25%
Monthly Changes
25%
Pulmonary Fibrosis
25%
Clinical Trials
12%
Adverse Events
12%
Antifibrotic
12%
Renal Function
12%
Multiple Sclerosis
12%
Treatment Duration
12%
Patient-completed
12%
Sedation
12%
Hepatic Cirrhosis
12%
Placebo-controlled Trial
12%
Renal Fibrosis
12%
Egfr
12%
Phototoxic Dermatitis
12%
Angiotensin Antagonists
12%
Proteinuria
12%
Open-label Trial
12%
Dyspepsia
12%
Decline Rate
12%
Kidney Disease Progression
12%
Medicine and Dentistry
Kidney Function
100%
Focal Segmental Glomerulosclerosis
100%
Pirfenidone
100%
Pulmonary Fibrosis
25%
Adverse Event
12%
Clinical Trial
12%
Liver Cirrhosis
12%
Antifibrotic Agent
12%
Placebo
12%
Open-Label Trial
12%
Chronic Kidney Disease
12%
Proteinuria
12%
Kidney Fibrosis
12%
Angiotensin Antagonist
12%
Dermatitis
12%
Multiple Sclerosis
12%
Stomach Acid
12%
Pharmacology, Toxicology and Pharmaceutical Science
Pirfenidone
100%
Focal Glomerulosclerosis
100%
Lung Fibrosis
25%
Placebo
12%
Adverse Event
12%
Clinical Trial
12%
Antifibrotic Agent
12%
Chronic Kidney Failure
12%
Multiple Sclerosis
12%
Liver Cirrhosis
12%
Open-Label Trial
12%
Dermatitis
12%
Kidney Fibrosis
12%
Proteinuria
12%
Angiotensin Antagonist
12%
Stomach Acid
12%